Pyruvate Kinase Function Correlates With Red Blood Cell Properties and Clinical Manifestations in Sickle Cell Disease
- PMID: 39981576
- PMCID: PMC11966359
- DOI: 10.1002/ajh.27644
Pyruvate Kinase Function Correlates With Red Blood Cell Properties and Clinical Manifestations in Sickle Cell Disease
Erratum in
-
Correction to "Pyruvate Kinase Function Correlates With Red Blood Cell Properties and Clinical Manifestations in Sickle Cell Disease".Am J Hematol. 2025 Aug;100(8):1471. doi: 10.1002/ajh.27713. Epub 2025 May 21. Am J Hematol. 2025. PMID: 40396686 Free PMC article. No abstract available.
Abstract
Pyruvate kinase (PK) is a key enzyme involved in the final step of glycolysis, essential to produce adenosine triphosphate (ATP). Relatively decreased red blood cell (RBC) PK activity (reflected by a lower PK/hexokinase [HK] ratio) and PK thermostability (PK activity after exposure to heat) were recently identified as pathophysiological features of sickle cell disease (SCD). In this study, we investigated whether impaired PK function is associated with sickle RBC properties and SCD-related clinical manifestations. This study included 97 non-transfused patients with SCD (88 HbSS, 9 HbS/β0 thalassemia). PK thermostability was correlated with RBC parameters such as reticulocyte count (r = -0.402, p < 0.0001) and hemoglobin F (r = 0.394, p < 0.0001), and indicators of impaired functional properties of sickle RBCs, such as the point of sickling (r = -0.417, p < 0.0001), oxygen affinity (r = 0.408, p < 0.001) and RBC adhesion to laminin (r = -0.322, p = 0.024). Additionally, a low PK/HK ratio correlated with decreased PK thermostability (r = 0.308, p = 0.002), decreased RBC deformability (r = 0.268, p = 0.009), and elevated 2,3-diphosphoglycerate levels (r = -0.244, p = 0.016). Multivariate Poisson regression analysis demonstrated that reduced PK thermostability and PK/HK ratio were associated with a higher incidence of SCD-related clinical complications. For every 10-unit decrease in PK thermostability and 1-unit decrease in PK/HK ratio, the incidence of SCD-related clinical complications increased by 11% (p = 0.012) and 10% (p = 0.019), respectively. Altogether, these findings indicate that impaired PK function is related to compromised sickle RBC properties and SCD-related clinical manifestations. This supports the relevance and underlines the potential of PK activation therapy.
Keywords: pyruvate kinase; red cells metabolism; sickle cell disease.
© 2025 The Author(s). American Journal of Hematology published by Wiley Periodicals LLC.
Conflict of interest statement
M.J.M.T., M.J.v.D., and J.R.A.d.W. received research funding from Agios Pharmaceuticals Inc. M.N.L. received research funding from ZonMW, LeoPharma, and INVENT‐VTE; reports consultancy fees (all to institute) from BMS/Pfizer, Amgen, Inari, Viatris, Servier, and AbbVie. M.H.C. received research funding from Takeda, Pfizer, Bayer, CSL Behring, Novo Nordisk, Novartis, Nordic Pharma; reports advisory or consulting role with Roche, Bayer, and Novartis. E.N. received research funding from Novartis; reports consulting role with Novartis and Vertex. B.J.B. received research funding from Sanquin, BMS, Pfizer, and Novartis; received honoraria from Sanofi; reports advisory board participation with Celgene, CSL Behring, Pfizer, and Novo Nordisk. E.J.v.B. received research funding from Agios Pharmaceuticals Inc.; reports consulting role with Agios Pharmaceuticals Inc. and Pfizer. A.W.R. received honoraria from Pfizer, Vertex pharmaceuticals, BMS, and Servier. R.v.W. received research funding from Agios Pharmaceuticals Inc. and Pfizer; reports consulting role with Agios Pharmaceuticals Inc., Pfizer, and RR Mechatronics. M.A.E.R. received research funding from Agios Pharmaceuticals Inc. and Pfizer; reports consulting role with RR Mechatronics. The other authors declare no conflicts of interest.
Figures
References
-
- Ware R. E., de Montalembert M., Tshilolo L., and Abboud M. R., “Sickle Cell Disease,” Lancet 390, no. 10091 (2017): 311–323. - PubMed
-
- Rees D. C., Williams T. N., and Gladwin M. T., “Sickle‐Cell Disease,” Lancet 376, no. 9757 (2010): 2018–2031. - PubMed
-
- Piel F. B., Steinberg M. H., and Rees D. C., “Sickle Cell Disease,” New England Journal of Medicine 376, no. 16 (2017): 1561–1573. - PubMed
-
- van Dijk M. J., de Wilde J. R. A., Bartels M., et al., “Activation of Pyruvate Kinase as Therapeutic Option for Rare Hemolytic Anemias: Shedding New Light on an Old Enzyme,” Blood Reviews 61 (2023): 101103. - PubMed
-
- Jensen M., Shohet S. B., and Nathan D. G., “The Role of Red Cell Energy Metabolism in the Generation of Irreversibly Sickled Cells in Vitro,” Blood 42, no. 6 (1973): 835–842. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
